Imaging advances in the management of kidney cancer

Katherine M. Krajewski, Ivan Pedrosa

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer. A host of imaging response criteria have been developed to characterize the response to targeted and immune therapies and correlate with patient outcomes, each with strengths and limitations. Recent efforts to advance the field are aimed at increasing objectivity with quantitative techniques and the use of banks of imaging data to match the vast genomic data that are becoming available. The emerging field of radiogenomics has the potential to transform further the role of imaging in kidney cancer management through eventual noninvasive characterization of the tumor histology and genetic microenvironment in single renal masses and/or metastatic disease. We review of the effect of currently available imaging techniques in the management of patients with kidney cancer, including localized, locally advanced, and metastatic disease.

Original languageEnglish (US)
Pages (from-to)3582-3590
Number of pages9
JournalJournal of Clinical Oncology
Volume36
Issue number36
DOIs
StatePublished - Dec 20 2018

Fingerprint

Kidney Neoplasms
Kidney
Single-Photon Emission-Computed Tomography
Positron-Emission Tomography
Histology
Tomography
Magnetic Resonance Imaging
Databases
Biopsy
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Imaging advances in the management of kidney cancer. / Krajewski, Katherine M.; Pedrosa, Ivan.

In: Journal of Clinical Oncology, Vol. 36, No. 36, 20.12.2018, p. 3582-3590.

Research output: Contribution to journalReview article

Krajewski, Katherine M. ; Pedrosa, Ivan. / Imaging advances in the management of kidney cancer. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 36. pp. 3582-3590.
@article{823ab5ac43e34193992b108c62e2e5a8,
title = "Imaging advances in the management of kidney cancer",
abstract = "New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer. A host of imaging response criteria have been developed to characterize the response to targeted and immune therapies and correlate with patient outcomes, each with strengths and limitations. Recent efforts to advance the field are aimed at increasing objectivity with quantitative techniques and the use of banks of imaging data to match the vast genomic data that are becoming available. The emerging field of radiogenomics has the potential to transform further the role of imaging in kidney cancer management through eventual noninvasive characterization of the tumor histology and genetic microenvironment in single renal masses and/or metastatic disease. We review of the effect of currently available imaging techniques in the management of patients with kidney cancer, including localized, locally advanced, and metastatic disease.",
author = "Krajewski, {Katherine M.} and Ivan Pedrosa",
year = "2018",
month = "12",
day = "20",
doi = "10.1200/JCO.2018.79.1236",
language = "English (US)",
volume = "36",
pages = "3582--3590",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Imaging advances in the management of kidney cancer

AU - Krajewski, Katherine M.

AU - Pedrosa, Ivan

PY - 2018/12/20

Y1 - 2018/12/20

N2 - New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer. A host of imaging response criteria have been developed to characterize the response to targeted and immune therapies and correlate with patient outcomes, each with strengths and limitations. Recent efforts to advance the field are aimed at increasing objectivity with quantitative techniques and the use of banks of imaging data to match the vast genomic data that are becoming available. The emerging field of radiogenomics has the potential to transform further the role of imaging in kidney cancer management through eventual noninvasive characterization of the tumor histology and genetic microenvironment in single renal masses and/or metastatic disease. We review of the effect of currently available imaging techniques in the management of patients with kidney cancer, including localized, locally advanced, and metastatic disease.

AB - New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer. A host of imaging response criteria have been developed to characterize the response to targeted and immune therapies and correlate with patient outcomes, each with strengths and limitations. Recent efforts to advance the field are aimed at increasing objectivity with quantitative techniques and the use of banks of imaging data to match the vast genomic data that are becoming available. The emerging field of radiogenomics has the potential to transform further the role of imaging in kidney cancer management through eventual noninvasive characterization of the tumor histology and genetic microenvironment in single renal masses and/or metastatic disease. We review of the effect of currently available imaging techniques in the management of patients with kidney cancer, including localized, locally advanced, and metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=85058566384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058566384&partnerID=8YFLogxK

U2 - 10.1200/JCO.2018.79.1236

DO - 10.1200/JCO.2018.79.1236

M3 - Review article

C2 - 30372386

AN - SCOPUS:85058566384

VL - 36

SP - 3582

EP - 3590

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -